Daptomycin

證據等級: L5

預測適應症: 10 個

Daptomycin: From Gram-Positive Infections to Osteoarthritis

One-Sentence Summary

Daptomycin is a cyclic lipopeptide antibiotic approved internationally (though not currently marketed in Canada) for complicated skin and soft tissue infections, Staphylococcus aureus bacteremia, and right-sided infective endocarditis caused by Gram-positive bacteria. The TxGNN model predicts it may be relevant to Osteoarthritis (OA), supported by 0 clinical trials and 10 publications — however, all retrieved literature documents daptomycin’s role in treating Gram-positive joint infections complicating OA surgery, not OA disease modification. Of note, the rank-2 prediction Rheumatoid Arthritis (score: 99.84%) carries more mechanistically compelling emerging evidence from 2025 preclinical studies and warrants a separate focused review.

Quick Overview

Item	Content
Original Indication	No Canadian license on file; internationally approved for Gram-positive bacterial infections (bacteremia, skin/soft-tissue infections, right-sided endocarditis)
Predicted New Indication	Osteoarthritis
TxGNN Prediction Score	99.86%
Evidence Level	L4
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, daptomycin is a cyclic lipopeptide antibiotic that inserts into the bacterial cell membrane in a calcium-dependent manner, causing membrane depolarization and inhibition of protein, DNA, and RNA synthesis. Its activity against Gram-positive organisms — including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci — is well established in clinical settings.

The connection between daptomycin and osteoarthritis is indirect and contextual rather than mechanistic. OA patients frequently undergo total knee or hip arthroplasty, which carries a risk of prosthetic joint infection (PJI) caused by Gram-positive bacteria. Daptomycin — particularly at high doses (>6 mg/kg) in combination with rifampicin — has been used as a salvage or second-line antibiotic for these PJIs. All 10 publications retrieved for this indication sit within this infection-management context; none evaluate daptomycin as a disease-modifying agent for OA itself. The TxGNN prediction likely reflects shared knowledge-graph node proximity between OA and Gram-positive osteoarticular infections rather than a biologically grounded treatment relationship.

A more scientifically compelling prediction is Rheumatoid Arthritis (rank 2, TxGNN score: 99.84%). A 2025 preclinical study (PMID 39571268) demonstrated that daptomycin suppresses collagen-induced arthritis in mice via inhibition of the NF-κB signaling pathway and downregulation of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β — all central to RA pathogenesis. A companion study (PMID 40923559, 2025) reported daptomycin-derived cyclic lipopeptide analogs with enhanced anti-inflammatory activity in both in vitro and animal models. These findings reveal a potential immunomodulatory dimension beyond classical antibacterial action, though human data remain entirely absent. Any repurposing evaluation for inflammatory joint disease should pivot to this RA signal rather than to OA.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
17999973	2008	Retrospective comparative	J Antimicrob Chemother	Daptomycin vs. standard therapy for osteoarticular infections associated with S. aureus bacteremia; evaluated clinical characteristics and outcomes
23519823	2013	Retrospective cohort	Int Orthop	High-dose daptomycin + rifampicin for various Gram-positive osteoarticular infections; assessed safety and efficacy of the combination regimen
22511636	2012	Retrospective case series	J Antimicrob Chemother	Daptomycin for knee and hip PJI; evaluated clinical efficacy and tolerability in periprosthetic infections
26235888	2015	Retrospective cohort	Int J Antimicrob Agents	High-dose daptomycin (>6 mg/kg) for complicated bone, joint, and implant-associated Gram-positive infections; safety and outcome data
21477701	2010	Registry / Observational	Med Clin	EU-CORE registry: real-world daptomycin use in Spanish hospitals including osteoarticular infection cases; demographic and outcome summary
23312602	2013	Survey	Int J Antimicrob Agents	Survey of PJI management among 556 infectious disease physicians; daptomycin preference patterns and antibiotic selection rationale
22854340	2012	In vitro	J Antibiot	Daptomycin susceptibility of S. aureus and S. epidermidis isolated from PJI; includes methicillin-resistant strain profiles
25650692	2015	Retrospective microbiological	Surg Infect	10-year microbiologic profile of Staphylococci causing osteoarticular infections; antibiotic susceptibility trends informing treatment selection
32206362	2020	Case report	Case Rep Orthop	Corynebacterium striatum septic arthritis in an OA patient referred for total knee arthroplasty; daptomycin used in infection management
41853106	2026	Case report	ASM Case Reports	First reported isolation of Corynebacterium propinquum from synovial fluid in native joint septic arthritis; daptomycin included in treatment discussion

Canada Market Information

Daptomycin currently has no licensed products (DINs) in Canada. No regulatory submissions or approved indications are on file in the Canadian market as of the data cutoff (2026-04-04).

Safety Considerations

Please refer to the package insert for safety information.

Note: Safety data (key warnings, contraindications, and drug interactions) were not available in this Evidence Pack. Clinicians should consult the international prescribing information (e.g., Cubicin® product monograph) for full safety details, including known risks such as myopathy, elevated creatine phosphokinase (CPK), eosinophilic pneumonia, and non-susceptibility emergence with prolonged use.

Conclusion and Next Steps

Decision: Hold

Rationale: All retrieved osteoarthritis-associated literature reflects daptomycin’s use as an antibiotic for treating Gram-positive joint infections that arise in OA patients — not as a direct treatment for OA. There is no biological mechanism by which an antibacterial agent would modify the degenerative cartilage pathology of osteoarthritis, and no clinical trial has examined this hypothesis. The TxGNN high score (99.86%) most likely reflects knowledge-graph node proximity rather than a genuine therapeutic relationship.

To proceed, the following is needed:

Re-route evaluation to Rheumatoid Arthritis (rank 2): The 2025 preclinical evidence of daptomycin suppressing NF-κB and RA-relevant cytokines (PMID 39571268, PMID 40923559) represents a biologically plausible repurposing hypothesis that warrants a dedicated evidence synthesis
Mechanistic data retrieval: Obtain full MOA data from DrugBank API (currently listed as data gap) to formally characterize anti-inflammatory pathway engagement
Safety profile completion: Retrieve key warnings and contraindications from the international product monograph (myopathy risk, CPK monitoring requirements, pulmonary toxicity signal)
Dose-response evaluation: Anti-inflammatory effects in preclinical studies may require doses distinct from antibacterial doses; a Phase 1 PK/PD study in healthy volunteers would be a prerequisite before any inflammatory disease indication is pursued
Canadian regulatory pathway assessment: Daptomycin has no Canadian DIN; any repurposing program would require a new drug submission or Notice of Compliance application to Health Canada
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.